Ignite Creation Date:
2025-12-24 @ 3:37 PM
Ignite Modification Date:
2026-01-24 @ 6:31 AM
Study NCT ID:
NCT01238692
Status:
COMPLETED
Last Update Posted:
2023-03-24
First Post:
2010-11-10
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)
Sponsor:
Sarit Assouline
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
Q-CROC-02
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None